Trials / Terminated
TerminatedNCT00203151
A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus
A Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of Edratide for Subcutaneous Injection in Systemic Lupus Erythematosus (SLE)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 340 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
It is thought that Edratide may be able to reduce the symptoms of SLE.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | edratide | 0.5 mg, 1.0 mg, 2.5 mg injection once weekly |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2007-02-01
- Completion
- 2007-02-01
- First posted
- 2005-09-20
- Last updated
- 2011-04-12
Source: ClinicalTrials.gov record NCT00203151. Inclusion in this directory is not an endorsement.